Teva Pharmaceutical Industries (NYSE:TEVA) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET

Company Participants

Ran Meir - Senior Vice President, Investor Relations

Richard Francis - President and Chief Executive Officer, Member of the Board of Directors

Eric Hughes - Executive Vice President, Global R&D and Chief Medical Officer

Eli Kalif - Executive Vice President, Chief Financial Officer

Sven Dethlefs - Executive Vice President, North America Commercial

Conference Call Participants

Umer Raffat - Evercore ISI

Balaji Prasad - Barclays

Jason Gerberry - Bank of America Merrill Lynch

Nathan Rich - Goldman Sachs

Glen Santangelo - Jefferies

David Amsellem - Piper Sandler

Operator

Hello, and welcome to the Q3 2023 Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex. I'll be coordinating the call today. [Operator instructions] I will now hand over to your host, Ran Meir, SVP of Investor Relations. Please go ahead.

Ran Meir

Thank you, Alex. Thank you, everyone, for joining us today. We hope you have had the opportunity to review our press release, which was issued earlier this morning. A copy of this press release, as well as a copy of the slides being presented on this call, can be found on our website at tevapharm.com.

Please review our forward-looking statements on Slide no. 2. Additional information regarding these statements and our non-GAAP financial measures is available on our earnings release and in our SEC Forms 10-K and 10-Q. To being today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's Q3 results and business performance, recent events and our priorities going forward.

Then Dr. Eric Hughes, our Head of R&D and Chief Medical Officer, will discuss progress on our innovative pipeline. Our CFO, Eli Kalif, will follow up by reviewing the financial results in more detail including our 2023 financial outlook.

Joining Richard, Eric, and Eli on the call today is Sven Dethlefs, Head of North America business, who will be available during the question-and-answer session that will follow the presentation. Please note that today's call will run approximately one hour. And with that, I will now turn the call over to Richard. Richard?

Richard Francis

Thank you. Ran. And thank you everybody for joining us today. I like to begin by saying that we are deeply saddened by the terror attack in Israel on October 7. Since that day, Teva’s board, leadership team and I have made the safety and wellbeing of our Israeli colleagues our upmost priority. I visited and met employees of the facility in Israel immediately after the attack. Many have families and friends who have perished or being kidnapped. What really stood out and inspired me was that despite all the difficulties, they are running together to bring medicines to the patients who need them, especially now.